N/A N=200 A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon
Coronary Stenosis · Coronary Artery Stenosis · In-stent Restenosis
Primary: Procedure Success — 176 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Remineralization of Molar Incisor Hypomineralization (MIH) With a Hydroxyapatite Toothpaste
Molar Incisor Hypomineralization
Primary: Change in Mineral Density (MD) of Tooth — 26.02; 14.64; 29.26; 16.83 percentage of remineralization
N/A N=3 Combined CBIT and rTMS to Improve Tourette's Syndrome
Tourette Syndrome
Primary: Tic Severity — 59.3; 43.3; 37.67 score on a scale — p=0.1997
N/A N=526 Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
Sars-CoV2 · Serum; Disease
Primary: Rate of Positive Serological Immune Status to a Previous Infection by the SARS-CoV-2 Virus at Inclusion — 18 Participants
Early Phase 1 N=27 Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Breast Cancer · Non-Small-Cell Lung Cancer · Glioblastoma
Primary: Tracer Dosimetry by Organ — 0.3603; 0.0988; 0.8615; 0.5290 mSv/MBq
Phase 4 N=162 Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis
Perforated Appendicitis · Postoperative Infection
Primary: Number of Participants With a Postoperative Intra-abdominal Abscess — 19; 5 Participants
Phase 3 N=431 TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Acute Leukemia · Chronic Myelogenous Leukemia (CML) · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) at One Year — 52.3; 35.5 percentage of participants — p=0.001
Phase 1 N=24 A Study of TAK-881 in Healthy Adults
Healthy Volunteers
Primary: Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site — 8; 8; 8; 4 Participants
N/A N=1,385 Sleep to Prevent Evolving Affecting Disorders
Insomnia, Primary · Depression
Primary: Severity of Depression as Measured by the Quick Inventory of Depressive Symptomatology (QIDS) Pre-Treatment — 10.8; 10.8 score on a scale
N/A N=26 Improving Care Coordination for Adolescents and Young Adults With Cancer
Cancer
Primary: Feasibility of Intervention Measure (FIM) AYA — 4.52 units on a scale
N/A N=317 Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Breast Cancer
Primary: Time to Chemotherapy — NA Weeks
Phase 1 N=31 Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
Duchenne and Becker Muscular Dystrophy · Polycytemia Vera
Primary: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF) — 1.0; 0.5; 10.2; 0.3 Milliseconds (msec)
Phase 2 N=11 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Cancer of Head and Neck · Cancer of Cervix · Cancer of Anus
Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants
Phase 2 N=68 Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC
Lung Cancer
Primary: Progression-free Survival — 11.5 months
N/A N=35,953 Cancer Prevention Clinical Decision Support
Cancer Prevention
Primary: Composite Cancer Screening Tests up to Date — 3087; 2590; 3866 Participants — p=.025